美国食品和药物管理局禁止非品牌减肥和糖尿病药物,因为安全问题. FDA bans off-brand versions of weight loss and diabetes drugs due to safety concerns.

林业发展局设定了终止销售非品牌减重和糖尿病药物(如Ozempic和Wegovy)的截止日期, The FDA has set a deadline to stop the sale of off-brand versions of weight loss and diabetes drugs like Ozempic and Wegovy, effective this week. 这些由复合药店制造的廉价替代品是为了满足高需求和解决2022年短缺问题而生产的。 These cheaper alternatives, made by compounding pharmacies, were produced to meet high demand and address shortages in 2022. 美国食品和药物管理局现在担心它们的安全性和监管. However, the FDA is now concerned about their safety and regulation. 这一举动可能影响到数千名病人,他们一直在使用低成本的复合GLP-1类药物。 This move may affect thousands of patients who have been using the lower-cost compounded GLP-1 drugs.